Related Experiment Video

Updated: Jun 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pharmacological strategies for lowering LDL cholesterol: statins and beyond

Ariel Brautbar1, Christie M Ballantyne

  • 1Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, 6565 Fannin, M.S. A-601, Houston, TX 77030, USA.

Nature Reviews. Cardiology
|February 16, 2011
PubMed

Insights

Lowering LDL cholesterol (low-density lipoprotein cholesterol) significantly reduces cardiovascular disease (CVD) risk. Clinical trials support progressively lower LDL-C goals, especially with potent statins, for effective CVD prevention.

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • A continuous, graded relationship exists between low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular disease (CVD) risk.
  • Clinical trials, particularly with high-potency statins, have confirmed this relationship at progressively lower LDL-C levels.
  • Guidelines recommend progressively lower LDL-C goals for patients stratified by absolute CVD risk.

Purpose of the Study:

  • To review the evidence supporting lower LDL-C goals for CVD prevention.
  • To discuss current therapeutic strategies for achieving LDL-C goals.
  • To highlight the potential of investigational agents for managing elevated LDL-C.

Main Methods:

  • Review of clinical trial evidence on LDL-C reduction and CVD risk.
  • Analysis of current guidelines for cholesterol management.
  • Discussion of pharmacological therapies, including statins and other agents.
  • Consideration of investigational agents for LDL-C lowering.

Main Results:

  • Clinical trial data consistently demonstrate a graded relationship between LDL-C and CVD risk.
  • High-potency statins achieve greater LDL-C reductions, supporting lower treatment goals.
  • Current guidelines recommend risk-stratified LDL-C targets for cholesterol management.
  • Statins are first-line therapy, often combined with other agents for optimal LDL-C reduction.
  • Investigational agents offer new mechanisms for LDL-C lowering, especially for genetic dyslipidemia.

Conclusions:

  • Lowering LDL-C is a cornerstone of cardiovascular disease prevention.
  • Risk-stratified LDL-C goals, guided by clinical trial evidence, are essential.
  • Pharmacological therapies, including statins and emerging agents, are crucial for achieving optimal LDL-C levels.
  • Further research into novel LDL-C-lowering mechanisms is needed for challenging cases like genetic dyslipidemia.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...